Latest Health News

Ecofibre Limited has restructured its Australian loan facilities, extending repayment terms and adjusting interest rates to support a more sustainable financial footing.

Forbidden Foods Limited has raised $1 million to boost inventory for its Blue Dinosaur and Oat Milk Goodness brands, following a remarkable 104% jump in quarterly sales.

LGI Limited reports a solid H1 FY25 performance with modest revenue growth and increased EBITDA, driven by expanded biogas flows and carbon abatement activities. The company confirms a positive outlook with a 12-15% underlying EBITDA growth forecast for FY25.

Artrya Limited has launched a A$15 million capital raising to fund the development and commercial rollout of its Salix AI-powered coronary artery disease diagnostic platform, targeting the lucrative US healthcare market.

AMP Limited’s FY24 Data Pack outlines a solid underlying profit performance despite headwinds, with key insights into its banking, platform, and wealth management divisions.

Civmec’s 1H FY25 results reveal robust revenue growth and a strong balance sheet, underpinned by a diversified project pipeline and strategic moves into naval shipbuilding and material handling equipment manufacturing.

HealthCo Healthcare & Wellness REIT reported a solid 5% increase in Funds From Operations (FFO) and Distribution Per Unit (DPU) for the first half of FY25, underpinned by stable asset valuations and a robust healthcare portfolio.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Unibail-Rodamco-Westfield delivered robust FY-2024 results with a 7% rise in like-for-like EBITDA and adjusted recurring EPS surpassing guidance, supported by strong retail and convention business performance. The company also announced a 40% increase in its proposed dividend, reflecting confidence in its financial health and strategic asset management.

Prophecy International Holdings has posted a record half-year revenue of $11.6 million for H1 FY25, driven by strong demand for its AI-enabled cybersecurity and data integration products. The company’s transition to subscription models and expansion into new global markets underpin a positive outlook.

Pro Medicus has delivered a record first half in FY25, driven by strong revenue growth, major contract wins, and successful implementations that position it well for future expansion.

Pro Medicus Limited has announced a fully franked ordinary dividend of AUD 0.25 per share for the six months ending December 2024, signaling continued shareholder returns without the need for external approvals.